This second volume of Strategic Patent and Commercialization Journey of Nemonoxacin examines the molecule's progression through the most consequential stages of its development. Moving from late-phase clinical evaluation to regulatory negotiation, manufacturing scale-up, and early post-approval deployment, the narrative situates Nemonoxacin within the broader scientific and policy environment shaping antimicrobial innovation.
Central to this account is TaiGen's systematic construction of a durable intellectual property and life-cycle management strategy. Through data-driven patent generation, jurisdiction-specific protection plans, and targeted extensions of clinical and formulation claims, the company sought to secure long-term market viability in a competitive therapeutic domain.
Set against shifting regional politics and Taiwan's growing biotech ambitions, this volume offers a close, unvarnished look at how a medicine survives the long arc from development to market - and how a company uses every lever available, from clinical evidence to life-cycle management, to keep that arc intact.
For readers interested in the human and strategic story behind drug development, it is both a case study and a record of a pivotal moment in Taiwan's scientific history.
外文書商品之書封，為出版社提供之樣本。實際出貨商品，以出版社所提供之現有版本為主。部份書籍，因出版社供應狀況特殊，匯率將依實際狀況做調整。
無庫存之商品，在您完成訂單程序之後，將以空運的方式為你下單調貨。為了縮短等待的時間，建議您將外文書與其他商品分開下單，以獲得最快的取貨速度，平均調貨時間為1~2個月。
為了保護您的權益，「三民網路書店」提供會員七日商品鑑賞期(收到商品為起始日)。
若要辦理退貨，請在商品鑑賞期內寄回，且商品必須是全新狀態與完整包裝(商品、附件、發票、隨貨贈品等)否則恕不接受退貨。
